In a nutshell This article reviewed the results of new targeted immunotherapy treatments in patients with classical Hodgkin’s lymphoma that is relapsed or refractory (does not respond to treatment). Some background Thanks to treatment advances, classical Hodgkin’s lymphoma (cHL) has become one of the most curable cancers. Frontline ABVD...
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Outcomes for NLPHL patients in daily clinical practice
In a nutshell This study reviewed the medical records of patients with nodular lymphocytic predominant Hodgkin's lymphoma (NLPHL) to evaluate their outcomes. This study concluded that all patients had excellent outcomes, even with a wide range of therapies. Some background Nodular lymphocytic predominant Hodgkin's lymphoma (NLPHL) is an...
Read MoreDoes prephase treatment help improve post-chemotherapy outcomes for newly diagnosed DLBCL patients?
In a nutshell This study investigated the outcomes of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients who received prephase treatment before chemotherapy. This study concluded that this treatment before chemotherapy improves symptoms and reduces chemotherapy-related side effects in these patients. Some background Diffuse large B-cell...
Read MoreWhat are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read MoreIs rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?
In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...
Read MoreWhat are the outcomes for B-cell lymphoma patients who receive salvage treatment for cancer that does not respond to R-CHOP chemotherapy?
In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...
Read MoreCan white blood cell count ratios help predict outcomes for newly diagnosed HL patients receiving PET2-mediated treatment?
In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...
Read MoreDoes brentuximab vedotin improve stem cell transplant outcomes for classical Hodgkin’s lymphoma patients?
In a nutshell This study investigated the outcomes of classical Hodgkin’s lymphoma (cHL) patients who did or did not receive brentuximab vedotin (Adcetris) before allogeneic stem cell transplantation. This study concluded that pre-transplant brentuximab vedotin treatment does not lead to better post-transplant outcomes. Some background...
Read MoreHow safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...
Read MoreLow-dose radiotherapy for low-grade lymphoma: What are the outcomes?
In a nutshell This study investigated the effectiveness, side effects, and relapse patterns of patients with low-grade (indolent; painless) follicular lymphoma (FL) or marginal zone lymphoma (MZL) after low-dose radiotherapy (LDRT). This study concluded that LDRT is an effective treatment in patients with low-grade disease and a low tumor burden. Some...
Read MoreWhat are the long-term outcomes following bendamustine treatment?
In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...
Read MoreDoes PET/CT scanning during chemotherapy improve IPI-based outcome predictions for DLBCL patients?
In a nutshell This study investigated whether interim FDG PET/CT scanning during chemotherapy helps predict risk for new DLBCL (diffuse large B-cell lymphoma) patients. This study concluded that this scanning improves the risk classifications used to predict outcomes for DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most...
Read More
